Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Change in Receivables (2021 - 2025)

HCW Biologics (HCWB) has disclosed Change in Receivables for 5 consecutive years, with $9056.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 389.05% year-over-year to $9056.0, compared with a TTM value of -$621173.0 through Sep 2025, down 966.59%, and an annual FY2024 reading of -$953556.0, down 185.29% over the prior year.
  • Change in Receivables was $9056.0 for Q3 2025 at HCW Biologics, up from -$65882.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $825678.0 in Q4 2023 and bottomed at -$1.2 million in Q2 2021.
  • Average Change in Receivables over 5 years is -$129964.9, with a median of -$3133.0 recorded in 2024.
  • The sharpest move saw Change in Receivables soared 1228.74% in 2023, then crashed 283.03% in 2024.
  • Year by year, Change in Receivables stood at $63000.0 in 2021, then decreased by 1.37% to $62140.0 in 2022, then skyrocketed by 1228.74% to $825678.0 in 2023, then crashed by 108.43% to -$69639.0 in 2024, then skyrocketed by 113.0% to $9056.0 in 2025.
  • Business Quant data shows Change in Receivables for HCWB at $9056.0 in Q3 2025, -$65882.0 in Q2 2025, and -$494708.0 in Q1 2025.